Radiosynthesis and in vivo evaluation of [ 11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A

Nuclear Medicine and Biology

Volumn 38, Issue 6, 2011, Pages 875-884

  Plisson, Christophe ^a   Salinas, Cristian ^a   Weinzimmer, David ^c   Labaree, David ^c   Lin, Shu Fei ^c   Ding, Yu Shin ^c   Jakobsen, Steen ^b   Smith, Paul W ^a   Eiji, Kawanishi ^d   Carson, Richard E ^c   Gunn, Roger N ^a   Rabiner, Eugenii A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Brain; Carbon 11; In vivo; MP 10; PDE10A; PET

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; 2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE C 11; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ARTICLE; BABOON; BRAIN STEM; BRAIN TISSUE; CAUDATE NUCLEUS; CEREBELLUM; CINGULATE GYRUS; COMPARTMENT MODEL; CONTROLLED STUDY; CORPUS STRIATUM; DIENCEPHALON; DRUG DISTRIBUTION; DRUG PURITY; DRUG SYNTHESIS; FRONTAL CORTEX; GLOBUS PALLIDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; IMAGE PROCESSING; IN VIVO STUDY; INSULA; ISOTOPE LABELING; NEUROIMAGING; NONHUMAN; NUCLEUS ACCUMBENS; OCCIPITAL CORTEX; PONS; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RADIOCHEMISTRY; SIGNAL TRANSDUCTION; SWINE; THALAMUS;

ANIMALS; CARBON RADIOISOTOPES; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; LIGANDS; PAPIO; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; QUINOLINES; RADIOCHEMISTRY; SUBSTRATE SPECIFICITY; SWINE;

EID: 80051693428     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.005     Document Type: Article

References (17)

1. Chappie T., Humphrey J., Menniti F., Schmidt C. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discovery Dev 2009, 12:458-467.
2. Girault J.A., Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004, 61:641-644.
3. Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 1999, 96:7071-7076.
4. Coskran T.M., Morton D., Menniti F.S., Adamowicz W.O., Kleiman R.J., Ryan A.M., et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006, 54:1205-1213.
5. Siuciak J.A., Strick C.A. Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia. Expert Opin Drug Discov 2007, 2:1001-1009.
6. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., Harms J.F., et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008, 325:681-690.
7. Hebb A., Robertson H., Denovan-Wright E.M. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004, 123:967-981.
8. Tu Z., Xu J., Jones L.A., Li S., Mach R.H. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol 2010, 37:509-516.
9. Celen S., Koole M., De Angelis M., Sannen I., Chitneni S.K., Alcazar J., et al. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 2010, 51:1584-1591.
10. Andrés-Gil JI, Bormans GM, De Angelis M, Celen SJL. Radiolabelled PDE10 ligands. WO2010/097367.
11. Grauer S.M., Pulito V.L., Navarra R.L., Kelly M.P., Kelley C., Graf R., et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009, 331:574-590.
12. Verhoest P.R., Chapin D.S., Corman M., Fonseca K., Harms J.F., Hou X., et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical. Candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 2009, 52:5188-5196.
13. 11C]MP10 as PET radiotracers for imaging PDE10A. J Nucl Med 2009, 50:161P.
14. Watanabe H., Andersen F., Simonsen C.Z., Evans S.M., Gjedde A., Cumming P. MR-based statistical atlas of the Gottingen minipig brain. Neuroimage 2001, 14:1089-1096.
15. Hilton J., Yokoi F., Dannals R.F., Ravert H.T., Szabo Z., Wong D.F. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 2000, 27:627-630.
16. Woods R.P., Grafton S.T., Holmes C.J., Cherry S.R., Mazziotta J.C. Automated image registration: I. General methods and intrasubject, intramodality validation. J Comput Assist Tomogr 1998, 22:139-152.
17. Cunningham V.J., Rabiner E.A., Slifstein M., Laruelle M., Gunn R.N. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 2010, 30:46-50.